Bioequivalence Studies of Dasatinib 100 Mg

Study acronym: BE-Dasatinib
StatusNot Yet Recruiting
PhasePhase 4
Started

Record status This record was last updated February 12, 2025 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 20, 2023 to Dec 20, 2025
    • Start date: Nov 1, 2023 to Sep 1, 2025
    • Study completion date: Jan 30, 2024 to Apr 30, 2026
    v2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose
Trial Details
NCT Number NCT05944783
Lead Sponsor Centro de Atencion e Investigacion Medica
Conditions
(from sponsor)		 Myeloma Multiple
Related terms Multiple Myeloma
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov